Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients
- PMID: 19302282
- DOI: 10.1111/j.1399-3062.2009.00380.x
Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients
Erratum in
- Transpl Infect Dis. 2009 Aug;11(4):382
Abstract
Aim: Transplant recipients are at risk for hospital-acquired infections (HAIs), including those caused by Pseudomonas aeruginosa. Of all HAIs, bloodstream infection (BSI) remains one of the most life-threatening.
Methods: Over a 10-year period, we studied 503 patients, including 149 transplant recipients, with pseudomonal BSI from the University of Pittsburgh Medical Center. Trends in antimicrobial susceptibility, risk factors for multidrug resistance (MDR), and outcomes were compared between transplant and non-transplant patients.
Results: Resistance to all antibiotic classes was significantly greater in pseudomonal blood culture isolates from transplant compared with non-transplant patients (P<0.001). Of isolates from transplant recipients (n=207), 43% were MDR, compared with 18% of isolates from non-transplant patients (n=391) (odds ratio [OR] 3.47; 95% confidence interval [CI] 2.34-5.14, P<0.001). Among all patients, independent risk factors for MDR P. aeruginosa BSI included previous transplantation (OR 2.38; 95% CI 1.51-3.76, P<0.001), hospital-acquired BSI (OR 2.41; 95% CI 1.39-4.18, P=0.002), and prior intensive care unit (ICU) admission (OR 2.04; 95% CI 1.15-3.63, P=0.015). Mortality among transplant recipients was 42%, compared with 32% in non-transplant patients (OR 1.55; 95% CI 0.87-2.76, P=0.108). For transplant recipients, onset of BSI in the ICU was the only independent predictor of mortality (OR 8.00; 95% CI 1.71-37.42, P=0.008).
Conclusions: Transplant recipients are at greater risk of MDR P. aeruginosa BSI, with an appreciable mortality. Future management must concentrate on the implementation of effective preventative strategies.
Similar articles
-
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.Epidemiol Infect. 2011 Nov;139(11):1740-9. doi: 10.1017/S0950268810003055. Epidemiol Infect. 2011. PMID: 21226988
-
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.Am J Infect Control. 2009 Nov;37(9):753-8. doi: 10.1016/j.ajic.2009.02.003. Epub 2009 May 31. Am J Infect Control. 2009. PMID: 19487049
-
Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients.Transpl Infect Dis. 2009 Oct;11(5):405-12. doi: 10.1111/j.1399-3062.2009.00421.x. Epub 2009 Jul 22. Transpl Infect Dis. 2009. PMID: 19638006
-
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.Clin Microbiol Infect. 2005 Jul;11 Suppl 4:17-32. doi: 10.1111/j.1469-0691.2005.01161.x. Clin Microbiol Infect. 2005. PMID: 15953020 Review.
-
Pseudomonas aeruginosa bloodstream infections: how should we treat them?Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S71-5. doi: 10.1016/j.ijantimicag.2007.06.015. Epub 2007 Aug 14. Int J Antimicrob Agents. 2007. PMID: 17698326 Review.
Cited by
-
The Distribution and Resistance of Pathogens Among Solid Organ Transplant Recipients with Pseudomonas aeruginosa Infections.Med Sci Monit. 2016 Apr 5;22:1124-30. doi: 10.12659/msm.896026. Med Sci Monit. 2016. PMID: 27045418 Free PMC article.
-
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.Drugs. 2021 Dec;81(18):2117-2131. doi: 10.1007/s40265-021-01635-6. Epub 2021 Nov 7. Drugs. 2021. PMID: 34743315 Free PMC article. Review.
-
Burden and Management of Multi-Drug Resistant Organism Infections in Solid Organ Transplant Recipients Across the World: A Narrative Review.Transpl Int. 2024 Jun 17;37:12469. doi: 10.3389/ti.2024.12469. eCollection 2024. Transpl Int. 2024. PMID: 38952482 Free PMC article. Review.
-
Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach.Antibiotics (Basel). 2022 May 2;11(5):612. doi: 10.3390/antibiotics11050612. Antibiotics (Basel). 2022. PMID: 35625256 Free PMC article. Review.
-
Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.Curr Infect Dis Rep. 2016 Jan;18(2):4. doi: 10.1007/s11908-015-0514-5. Curr Infect Dis Rep. 2016. PMID: 26743200
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical